Boston, MA — May 2026 — MileCell Bio, a provider of high-quality primary cell–based solutions for life science research, today announced that it will exhibit at the ASGCT 2026 Annual Meeting, taking place May 12–14, 2026, in Boston, Massachusetts.
Attendees are invited to visit Booth #1162 to explore MileCell’s portfolio of CGT-ready primary cells and reagents, designed to support research from early discovery through translational development in cell and gene therapy (CGT).
Advancing Cell & Gene Therapy Research
MileCell provides a comprehensive range of products tailored to the needs of CGT researchers, including:
- Primary hepatocytes and non-parenchymal cells for ADME and toxicology studies
- Immune cells, including PBMCs, T cells, B cells, NK cells, macrophages, and splenocytes*
- MagSep™ magnetic microbeads for immune cell isolation
- Kryogene cell freezing media (serum-free and CGT-ready)
- Subcellular fractions, including microsomes, S9, and cytosol
These solutions are widely used in applications such as:
- Cell therapy development
- Immuno-oncology research
- Viral vector and mRNA workflows
- ADME/DMPK and safety evaluation
*Human-derived immune cells are currently under development.
ASGCT 2026 Booth Promotion
During the meeting, MileCell will offer a complimentary sample of its Cell Freezing Media (Serum-Free / CGT-Ready)
Visitors can claim their free sample by:
- Registering on the MileCell website, or
- Following MileCell on LinkedIn
